FDA "Blue Ribbon" Panel
Executive Summary
Formula, Inc., an advocacy group involved in issues arising from the Syntex infant formula recall in 1979, is asking HHS Secretary Sullivan to remove Syntex President Paul Frieman from the panel because of his relationship to the infant formula situation as president of Syntex Labs when the recall was conducted. Syntex notes that the government chose not to prosecute the company or any executives as a followup to the situation.
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.